Summary

The assessment of disease activity and burden has evolved from one based on clinical activity to one based on radiologic criteria (eg, number of new/enlarging T2 lesions, number of gadolinium-enhancing [Gd+] lesions, and brain atrophy/black holes). Treatment has moved from slowing disease progression to treatments (eg, natalizumab, fingolimod, interferon beta-1b [IFN-β-1b]) that improve and sustain function.